Pharmaceuticals News and Research

RSS

2014 DIA patient fellows illustrate the power of patient advocacy

The 2014 DIA patient fellows illustrate the power of patient advocacy. A Parkinson's disease patient is the driving force in the success of clinical trials, recruiting patients and transporting them to research sites while saving researchers thousands of dollars.

9 Jun 2014

Mylan launches generic version of Bristol-Myers Squibb's Paraplatin Injection

Mylan Inc. today announced that it has launched Carboplatin Injection, 50 mg/5 ml, in multi-dose vials, which is the generic version of Bristol-Myers Squibb's Paraplatin® Injection.

9 Jun 2014

Manchester announces multi-year sponsorship deal with Cho-A Pharm

Manchester United has today announced a multi-year sponsorship deal with Korean Pharmaceutical company Cho-A Pharm to become Manchester United's Official Pharmaceuticals partner of in South Korea and Vietnam.

9 Jun 2014

Cubist Pharmaceuticals publishes positive results from Phase 3 clinical trial of SIVEXTRO

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that The Lancet Infectious Diseases published online the positive results from ESTABLISH-2, a pivotal Phase 3 clinical trial of the investigational antibiotic SIVEXTRO™ (tedizolid phosphate), which is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and complicated skin and soft tissue infections (cSSTI).

9 Jun 2014

Valeant Pharmaceuticals receives approval from FDA for treatment of onychomycosis

Valeant Pharmaceuticals International, Inc. today announced that that its wholly owned subsidiary, Valeant Pharmaceuticals North America LLC, received notice that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Jublia® (efinaconazole 10% topical solution), the first topical triazole approved for the treatment of onychomycosis of the toenails.

9 Jun 2014

Co-founder of Avidity Nanomedicines to receive 2014 Prince of Asturias Award

Avidity NanoMedicines LLC, a biopharmaceutical company pioneering a breakthrough approach to the targeted delivery of nucleic acid-based medicines, announced today that its scientific co-founder, Mark E. Davis, Ph.D., will receive the 2014 Prince of Asturias Award for Technical and Scientific Research.

9 Jun 2014

Actinium's Chairman to discuss role of alpha-particle radiopharmaceuticals at SNMMI Annual Meeting

Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that Actinium's Clinical Advisory Board Chairman Joseph Jurcic, MD will participate in an upcoming panel discussion highlighting the role of Actinium's alpha-particle radiopharmaceuticals in the treatment of leukemia patients.

9 Jun 2014

Advances in understanding of genetics of CAD lead to more therapeutic targets

Advances in the understanding of the genetics of coronary artery disease, or CAD, will revitalize the field and lead to more therapeutic targets for new medicines to combat this common disease, suggests a genetics expert from the Perelman School of Medicine at the University of Pennsylvania in a Perspective article in the new issue of Science Translational Medicine.

9 Jun 2014

Edison's EPI-743 receives FDA orphan drug designation for treatment of Leigh syndrome

Edison Pharmaceuticals today announced that the FDA has granted Orphan Drug status to vatiquinone for the treatment of Leigh syndrome.

9 Jun 2014

First Edition: June 6, 2014

Today's headlines include reports about the Senate confirmation of Sylvia Mathews Burwell to be the next secretary of the Department of Health and Human Services.

6 Jun 2014

New drug shows promising results in patients with advanced pancreatic cancer

A clinical trial conducted by researchers at the Virginia G. Piper Cancer Center Clinical Trials, a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute, showed that a new drug called MM-398, given in combination with 5-flourouracil (5FU) and leucovorin, produced a significant overall survival rate in patients with advanced, previously-treated pancreatic cancer.

6 Jun 2014

Tech Collective invites applications and nominations for 2014 Rhode Island Bioscience Awards

Tech Collective, Rhode Island's Bioscience and Information Technology industry association, today announces the launch of its 2014 Rhode Island Bioscience Awards.

6 Jun 2014

State highlights: NYC soda fight back in court; doc training slots in N.Y.; Texas inmate dialysis costs

New York City's battle over sugary drinks is entering its endgame. But much more than soda is at stake. A plan to limit the sale of large, high-calorie beverages, championed by former Mayor Michael R. Bloomberg as a novel way to fight obesity, went before the State Court of Appeals here on Wednesday, the city's final recourse after a lower court judge struck down the proposal last year (Grynbaum, 6/4).

6 Jun 2014

SGC and CHDI Foundation collaborate to discover new drug targets for Huntington's disease

The Structural Genomics Consortium (SGC) and CHDI Foundation have entered into a unique open-access research collaboration to discover and characterize new drug targets for Huntington's disease (HD) using structural and chemical biology In this first partnership of its kind, SGC and CHDI have explicitly agreed not to file for patents on any of the collaborative research and to make all reagents and knowledge available without restriction to the wider research community, including pharmaceutical, biotech, and academic research groups.

6 Jun 2014

Ocugen's OCU100 gets FDA orphan drug designation for treatment of retinitis pigmentosa

Ocugen, Inc. and the University of Colorado today announced exclusive license agreements that allow for Ocugen to continue developing two drug candidates for the treatment for ophthalmology indications, and that one of the assets, OCU100, recombinant lens epithelium derived growth factor 1-326 (LEDGF1-326), received orphan-drug status from the U.S. Food and Drug Administration for treatment of retinitis pigmentosa (RP), a rare eye disease.

6 Jun 2014

Tolero Pharmaceuticals reports positive interim results from alvocidib Phase 2 trial for AML treatment

Tolero Pharmaceuticals, Inc., a late clinical-stage biopharmaceutical company developing treatments for oncology and blood disorders, reported positive interim results from an ongoing, randomized Phase 2 clinical trial of its lead drug candidate, alvocidib, in combination with cytarabine plus mitoxantrone for previously untreated acute myeloid leukemia (AML) patients.

6 Jun 2014

$SAGE reports preliminary data from SAGE-547 Phase 1/2 clinical trial for super-refractory status epilepticus$

SAGE reports preliminary data from SAGE-547 Phase 1/2 clinical trial for super-refractory status epilepticus

SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced preliminary data from its ongoing open-label Phase 1/2 clinical trial of SAGE-547, an allosteric modulator of GABAA receptors, in patients with super-refractory status epilepticus (SRSE).

5 Jun 2014

Health policy researchers urge BMJ to widen its approach to transparency protocol

A group of New Zealand health policy researchers from the University of Otago's Dunedin and Christchurch campuses has called on the leading medical journal BMJ to be much more even handed in scrutinizing the transparency of what it publishes.

5 Jun 2014

Patient registry to help clinicians identify, manage people who have progressive lung disease

Duke Clinical Research Institute has launched a patient registry to help researchers and clinicians identify, manage and study people who have a progressive lung disease called idiopathic pulmonary fibrosis.

5 Jun 2014

NantHealth to unveil open Clinical Operating System at NHS Confederation Annual Conference and Exhibition

NantHealth, a transformational healthcare company converging science and technology through a single integrated clinical platform, will unveil the industry's first, open Clinical Operating System (cOS) for value-based, coordinated care at this year's NHS Confederation Annual Conference and Exhibition.

4 Jun 2014

Pharmaceuticals News and Research

2014 DIA patient fellows illustrate the power of patient advocacy

Mylan launches generic version of Bristol-Myers Squibb's Paraplatin Injection

Manchester announces multi-year sponsorship deal with Cho-A Pharm

Cubist Pharmaceuticals publishes positive results from Phase 3 clinical trial of SIVEXTRO

Valeant Pharmaceuticals receives approval from FDA for treatment of onychomycosis

Co-founder of Avidity Nanomedicines to receive 2014 Prince of Asturias Award

Actinium's Chairman to discuss role of alpha-particle radiopharmaceuticals at SNMMI Annual Meeting

Advances in understanding of genetics of CAD lead to more therapeutic targets

Edison's EPI-743 receives FDA orphan drug designation for treatment of Leigh syndrome

First Edition: June 6, 2014

New drug shows promising results in patients with advanced pancreatic cancer

Tech Collective invites applications and nominations for 2014 Rhode Island Bioscience Awards

State highlights: NYC soda fight back in court; doc training slots in N.Y.; Texas inmate dialysis costs

SGC and CHDI Foundation collaborate to discover new drug targets for Huntington's disease

Ocugen's OCU100 gets FDA orphan drug designation for treatment of retinitis pigmentosa

Tolero Pharmaceuticals reports positive interim results from alvocidib Phase 2 trial for AML treatment

SAGE reports preliminary data from SAGE-547 Phase 1/2 clinical trial for super-refractory status epilepticus

Health policy researchers urge BMJ to widen its approach to transparency protocol

Patient registry to help clinicians identify, manage people who have progressive lung disease

NantHealth to unveil open Clinical Operating System at NHS Confederation Annual Conference and Exhibition

Pittcon Highlights: Pharmaceutical & Biologic eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence